Beyond Eye Health
How Astaxanthin Combats Degenerative Disease
By Gail Richardson
The clinical importance of astaxanthin’s multi-targeted immune-modulating effects is clearly evident in the ways that astaxanthin fights off the bacterium called Helicobacter pylori (H. pylori). About half the world’s population is infected with this pathogen, which produces a spectrum of stomach disorders ranging from chronic gastritis and ulcers to gastric cancer.70
Astaxanthin mitigates the inflammation associated with H. pylori infection of the stomach.70 Animal studies indicate that astaxanthin inhibits the growth of H. pylori in the stomach.70,71 Astaxanthin has proven its efficacy in reducing symptoms of gastroesophageal reflux (heartburn, or GERD), especially in people with H. pylori infections.72
Astaxanthin and Ocular Disease Prevention
Loss of vision is a terrifying reality for millions of aging Americans. Three major age-associated causes of blindness are cataracts, age-related macular degeneration, and glaucoma. All of these are associated with chronic oxidative damage, and most involve some degree of inflammation.73 That makes powerful antioxidants such as astaxanthin of natural interest to prevention-oriented physicians.74
Astaxanthin decreases UV light-induced fat oxidation in cells of the human lens, which can help prevent cataract formation.71 That antioxidant effect helps prevent retinal damage.75 Astaxanthin also inhibits the pro-inflammatory nuclear factor-kappaB (NF-kB) signaling pathway in the eye.76,77 Early, preventive treatment with a combination of antioxidants including astaxanthin, lutein, zeaxanthin, vitamin C, vitamin E, zinc, and copper in humans at risk for age-related macular degeneration demonstrated improvement in vision near the important central part of the retina.78 Astaxanthin also helped reduce markers of inflammation and cell death in an animal model of glaucoma.79
Another promising application of astaxanthin is the prevention of eye fatigue or asthenopia, particularly in people who work long hours viewing a computer screen. In a study of 26 individuals who work at computer terminals, those who were randomly selected to receive astaxanthin each day for one month had a 54% reduction in complaints of eye fatigue, along with improvements in accommodation (your eyes’ ability to change optical power to focus on objects at different distances).80 A similar study showed that one month of astaxanthin reduced eye fatigue and increased accommodation power in healthy subjects.81 Researchers believe that astaxanthin may help fight eye fatigue in part by increasing blood flow to the retina.82
Natural UV Protection
A lifetime of exposure to ultraviolet (UV) light can trigger wrinkles and skin sagging, and it also dramatically increases the risk of skin cancer. Preliminary laboratory findings suggest that astaxanthin may represent a potential sun-protective agent that can be taken internally to block the damaging effects of UV radiation.83
Human skin cells in culture rapidly accumulate astaxanthin following treatment, and their vulnerability to UV light-induced oxidative damage is sharply reduced.84 That effect is accompanied by increased activity of cellular antioxidant systems and reduced cell membrane damage, while production of wrinkle- and sag-inducing skin enzymes is markedly reduced.11,83 It is little wonder that astaxanthin has been praised as promoting “beauty from within” in recent press releases.1
Astaxanthin has long been shown to protect aging eyes from cataracts, age-related macular degeneration, and glaucoma. More recent scientific findings indicate astaxanthin as a multimodal intervention for numerous forms of degenerative disease. These include cardiovascular disease, cancer, metabolic syndrome, cognitive decline, age-related immune dysfunction, stomach and eye conditions, and skin damage. Astaxanthin is safe in a wide range of doses. As little as 4-6 mg per day has been shown to effectively support eye health. Between 6 and 18 mg are indicated for management of metabolic syndrome. As much as 40 mg per day mitigates H. pylori-induced gastritis, with no side effects reported at any of these doses.18,33,78,85
If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.
1. Available at: http://www.nutraingredients-usa.com/Industry/Dr-Oz-and-Oprah-effect-sends-astaxanthin-demand-skyrocketing-claims-Cyanotech. Accessed April 8, 2011.
2. Hussein G, Sankawa U, Goto H, Matsumoto K, Watanabe H. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006 Mar;69(3):443-9.
3. Higuera-Ciapara I, Felix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006;46(2):185-96.
4. Jackson H, Braun CL, Ernst H. The chemistry of novel xanthophyll carotenoids. Am J Cardiol. 2008 May 22;101(10A):50D-7D.
5. Pashkow FJ, Watumull DG, Campbell CL. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol. 2008 May 22;101(10A):58D-68D.
6. Gross GJ, Hazen SL, Lockwood SF. Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats. Mol Cell Biochem. 2006 Feb;283(1-2):23-30.
7. Gross GJ, Lockwood SF. Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts. Mol Cell Biochem. 2005 Apr;272(1-2):221-7.
8. Lockwood SF, Gross GJ. Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc Drug Rev. 2005 Fall;23(3):199-216.
9. Khan SK, Malinski T, Mason RP, et al. Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thromb Res. 2010 Oct;126(4):299-305.
10. Chew BP, Park JS. Carotenoid action on the immune response. J Nutr. 2004 Jan;134(1):257S-61S.
11. Suganuma K, Nakajima H, Ohtsuki M, Imokawa G. Astaxanthin attenuates the UVA-induced up-regulation of matrix-metalloproteinase-1 and skin fibroblast elastase in human dermal fibroblasts. J Dermatol Sci. 2010 May;58(2):136-42.
12. Wolf AM, Asoh S, Hiranuma H, et al. Astaxanthin protects mitochondrial redox state and functional integrity against oxidative stress. J Nutr Biochem. 2010 May;21(5):381-9.
13. Kidd PM. Integrated brain restoration after ischemic stroke--medical management, risk factors, nutrients, and other interventions for managing inflammation and enhancing brain plasticity. Altern Med Rev. 2009 Mar;14(1):14-35.
14. Riccioni G. Carotenoids and cardiovascular disease. Curr Atheroscler Rep. 2009 Nov;11(6):434-9.
15. Bertram JS, Vine AL. Cancer prevention by retinoids and carotenoids: independent action on a common target. Biochim Biophys Acta. 2005 May 30;1740(2):170-8.
16. Kim YJ, Kim YA, Yokozawa T. Protection against oxidative stress, inflammation, and apoptosis of high-glucose-exposed proximal tubular epithelial cells by astaxanthin. J Agric Food Chem. 2009 Oct 14;57(19):8793-7.
17. Lorenz RT, Cysewski GR, Inventors; Cyanotech Corporation, assignee. Method of retarding and ameliorating carpal tunnel syndrome. US patent 6,258,855 July 10, 2001.
18. Spiller GA, Dewell A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: a randomized clinical trial. J Med Food. 2003 Spring;6(1):51-6.
19. McNulty H, Jacob RF, Mason RP. Biologic activity of carotenoids related to distinct membrane physicochemical interactions. Am J Cardiol. 2008 May 22;101(10A):20D-29D.
20. McNulty HP, Byun J, Lockwood SF, Jacob RF, Mason RP. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochim Biophys Acta. 2007 Jan;1768(1):167-74.
21. Goto S, Kogure K, Abe K, et al. Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta. 2001 Jun 6;1512(2):251-8.
22. Choi SK, Park YS, Choi DK, Chang HI. Effects of astaxanthin on the production of NO and the expression of COX-2 and iNOS in LPS-stimulated BV2 microglial cells. J Microbiol Biotechnol. 2008 Dec;18(12):1990-6.
23. Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. Anticancer Res. 2010 Jul;30(7):2721-5.
24. Wang HQ, Sun XB, Xu YX, Zhao H, Zhu QY, Zhu CQ. Astaxanthin upregulates heme oxygenase-1 expression through ERK1/2 pathway and its protective effect against beta-amyloid-induced cytotoxicity in SH-SY5Y cells. Brain Res. 2010 Nov 11;1360:159-67.
25. Santocono M, Zurria M, Berrettini M, Fedeli D, Falcioni G. Lutein, zeaxanthin and astaxanthin protect against DNA damage in SK-N-SH human neuroblastoma cells induced by reactive nitrogen species. J Photochem Photobiol B. 2007 Jul 27;88(1):1-10.
26. Palozza P, Torelli C, Boninsegna A, et al. Growth-inhibitory effects of the astaxanthin-rich alga Haematococcus pluvialis in human colon cancer cells. Cancer Lett. 2009 Sep 28;283(1):108-17.
27. Tripathi DN, Jena GB. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: Role of Nrf2, p53, p38 and phase-II enzymes. Mutat Res. 2010 Feb 1;696(1):69-80.
28. Park JS, Chyun JH, Kim YK, Line LL, Chew BP. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutr Metab (Lond). 2010;7:18.
29. Chew BP, Mathison BD, Hayek MG, Massimino S, Reinhart GA, Park JS. Dietary astaxanthin enhances immune response in dogs. Vet Immunol Immunopathol. 2011 Apr 15;140(3-4):199-206.
30. Fassett RG, Coombes JS. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009 Jul;5(4):333-42.
31. Hussein G, Nakagawa T, Goto H, et al. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci. 2007 Jan 16;80(6):522-9.
32. Uchiyama K, Naito Y, Hasegawa G, Nakamura N, Takahashi J, Yoshikawa T. Astaxanthin protects beta-cells against glucose toxicity in diabetic db/db mice. Redox Rep. 2002;7(5):290-3.
33. Yoshida H, Yanai H, Ito K, et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis. 2010 Apr;209(2):520-3.
34. Ikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem. 2007 Apr;71(4):893-9.
35. Preuss HG, Echard B, Yamashita E, Perricone NV. High dose astaxanthin lowers blood pressure and increases insulin sensitivity in rats: are these effects interdependent? Int J Med Sci. 2011;8(2):126-38.
36. Nagendraprabhu P, Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest New Drugs. 2011 Apr;29(2):207-24.
37. Prabhu PN, Ashokkumar P, Sudhandiran G. Antioxidative and antiproliferative effects of astaxanthin during the initiation stages of 1,2-dimethyl hydrazine-induced experimental colon carcinogenesis. Fundam Clin Pharmacol. 2009 Apr;23(2):225-34.
38. Nakao R, Nelson OL, Park JS, Mathison BD, Thompson PA, Chew BP. Effect of dietary astaxanthin at different stages of mammary tumor initiation in BALB/c mice. Anticancer Res. 2010 Jun;30(6):2171-5.
39. Wakshlag JJ, Balkman CA, Morgan SK, McEntee MC. Evaluation of the protective effects of all-trans-astaxanthin on canine osteosarcoma cell lines. Am J Vet Res. 2010 Jan;71(1):89-96.
40. Kurihara H, Koda H, Asami S, Kiso Y, Tanaka T. Contribution of the antioxidative property of astaxanthin to its protective effect on the promotion of cancer metastasis in mice treated with restraint stress. Life Sci. 2002 Apr 21;70(21):2509-20.
41. Jyonouchi H, Sun S, Iijima K, Gross MD. Antitumor activity of astaxanthin and its mode of action. Nutr Cancer. 2000;36(1):59-65.
42. Hussein G, Goto H, Oda S, et al. Antihypertensive potential and mechanism of action of astaxanthin: II. Vascular reactivity and hemorheology in spontaneously hypertensive rats. Biol Pharm Bull. 2005 Jun;28(6):967-71.
43. Hussein G, Goto H, Oda S, Sankawa U, Matsumoto K, Watanabe H. Antihypertensive potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in spontaneously hypertensive rats. Biol Pharm Bull. 2006 Apr;29(4):684-8.
44. Hussein G, Nakamura M, Zhao Q, et al. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull. 2005 Jan;28(1):47-52.
45. Monroy-Ruiz J, Sevilla MA, Carron R, Montero MJ. Astaxanthin-enriched-diet reduces blood pressure and improves cardiovascular parameters in spontaneously hypertensive rats. Pharmacol Res. 2011 Jan;63(1):44-50.
46. Li W, Hellsten A, Jacobsson LS, Blomqvist HM, Olsson AG, Yuan XM. Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits. J Mol Cell Cardiol. 2004 Nov;37(5):969-78.
47. Nishigaki I, Rajendran P, Venugopal R, Ekambaram G, Sakthisekaran D, Nishigaki Y. Cytoprotective role of astaxanthin against glycated protein/iron chelate-induced toxicity in human umbilical vein endothelial cells. Phytother Res. 2010 Jan;24(1):54-9.
48. Curek GD, Cort A, Yucel G, et al. Effect of astaxanthin on hepatocellular injury following ischemia/reperfusion. Toxicology. 2010 Jan 12;267(1-3):147-53.
49. Lauver DA, Lockwood SF, Lucchesi BR. Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion. J Pharmacol Exp Ther. 2005 Aug;314(2):686-92.
50. Gross GJ, Lockwood SF. Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax). Life Sci. 2004 May 28;75(2):215-24.
51. Wu Y, Yin X, Wijaya C, Huang MH, McConnell BK. Acute myocardial infarction in rats. J Vis Exp. 2011 Feb 16;(48).
52. Satoh A, Tsuji S, Okada Y, et al. Preliminary Clinical Evaluation of Toxicity and Efficacy of A New Astaxanthin-rich Haematococcus pluvialis Extract. J Clin Biochem Nutr. 2009 May;44(3):280-4.
53. Fassett RG, Healy H, Driver R, et al. Astaxanthin vs placebo on arterial stiffness, oxidative stress and inflammation in renal transplant patients (Xanthin): a randomised controlled trial. BMC Nephrol. 2008;9:17.
54. Liu X, Osawa T. Astaxanthin protects neuronal cells against oxidative damage and is a potent candidate for brain food. Forum Nutr. 2009;61:129-35.
55. Lin TY, Lu CW, Wang SJ. Astaxanthin inhibits glutamate release in rat cerebral cortex nerve terminals via suppression of voltage-dependent Ca(2+) entry and mitogen-activated protein kinase signaling pathway. J Agric Food Chem. 2010 Jul 28;58(14):8271-8.
56. Chang CH, Chen CY, Chiou JY, Peng RY, Peng CH. Astaxanthine secured apoptotic death of PC12 cells induced by beta-amyloid peptide 25-35: its molecular action targets. J Med Food. 2010 Jun;13(3):548-56.
57. Kim YH, Koh HK, Kim DS. Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-kappaB-mediated signals in activated microglia. Int Immunopharmacol. 2010 Dec;10(12):1560-72.
58. Nakagawa K, Kiko T, Miyazawa T, Carpentero Burdeos G, Kimura F, Satoh A. Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes. Br J Nutr. 2011 Jan 31:1-9.
59. Shen H, Kuo CC, Chou J, et al. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J. 2009 Jun;23(6):1958-68.
60. Nishioka Y, Oyagi A, Tsuruma K, Shimazawa M, Ishibashi T, Hara H. The antianxiety-like effect of astaxanthin extracted from Paracoccus carotinifaciens. Biofactors. 2011 Jan;37(1):25-30.
61. Hakim FT, Gress RE. Immunosenescence: deficits in adaptive immunity in the elderly. Tissue Antigens. 2007 Sep;70(3):179-89.
62. Jyonouchi H, Zhang L, Gross M, Tomita Y. Immunomodulating actions of carotenoids: enhancement of in vivo and in vitro antibody production to T-dependent antigens. Nutr Cancer. 1994;21(1):47-58.
63. Jyonouchi H, Sun S, Tomita Y, Gross MD. Astaxanthin, a carotenoid without vitamin A activity, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. J Nutr. 1995 Oct;125(10):2483-92.
64. Akyon Y. Effect of antioxidants on the immune response of Helicobacter pylori. Clin Microbiol Infect. 2002 Jul;8(7):438-41.
65. Macedo RC, Bolin AP, Marin DP, Otton R. Astaxanthin addition improves human neutrophils function: in vitro study. Eur J Nutr. 2010 Dec;49(8):447-57.
66. Aoi W, Naito Y, Sakuma K, et al. Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal. 2003 Feb;5(1):139-44.
67. Ikeuchi M, Koyama T, Takahashi J, Yazawa K. Effects of astaxanthin supplementation on exercise-induced fatigue in mice. Biol Pharm Bull. 2006 Oct;29(10):2106-10.
68. Aoi W, Naito Y, Takanami Y, et al. Astaxanthin improves muscle lipid metabolism in exercise via inhibitory effect of oxidative CPT I modification. Biochem Biophys Res Commun. 2008 Feb 22;366(4):892-7.
69. Yuan JP, Peng J, Yin K, Wang JH. Potential health-promoting effects of astaxanthin: a high-value carotenoid mostly from microalgae. Mol Nutr Food Res. 2011 Jan;55(1):150-65.
70. Bennedsen M, Wang X, Willen R, Wadstrom T, Andersen LP. Treatment of H. pylori infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes. Immunol Lett. 1999 Dec 1;70(3):185-9.
71. Wang X, Willen R, Wadstrom T. Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother. 2000 Sep;44(9):2452-7.
72. Kupcinskas L, Lafolie P, Lignell A, et al. Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine. 2008 Jun;15(6-7):391-9.
73. Ohia SE, Opere CA, Leday AM. Pharmacological consequences of oxidative stress in ocular tissues. Mutat Res. 2005 Nov 11;579(1-2):22-36.
74. Chitchumroonchokchai C, Bomser JA, Glamm JE, Failla ML. Xanthophylls and alpha-tocopherol decrease UVB-induced lipid peroxidation and stress signaling in human lens epithelial cells. J Nutr. 2004 Dec;134(12):3225-32.
75. Nakajima Y, Inokuchi Y, Shimazawa M, Otsubo K, Ishibashi T, Hara H. Astaxanthin, a dietary carotenoid, protects retinal cells against oxidative stress in-vitro and in mice in-vivo. J Pharm Pharmacol. 2008 Oct;60(10):1365-74.
76. Suzuki Y, Ohgami K, Shiratori K, et al. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res. 2006 Feb;82(2):275-81.
77. Izumi-Nagai K, Nagai N, Ohgami K, et al. Inhibition of choroidal neovascularization with an anti-inflammatory carotenoid astaxanthin. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1679-85.
78. Parisi V, Tedeschi M, Gallinaro G, Varano M, Saviano S, Piermarocchi S. Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology. 2008 Feb;115(2):324-33.
79. Cort A, Ozturk N, Akpinar D, et al. Suppressive effect of astaxanthin on retinal injury induced by elevated intraocular pressure. Regul Toxicol Pharmacol. 2010 Oct;58(1):121-30.
80. Available at: http://sciencelinks.jp/j-east/article/200301/000020030102A0904519.php. Accessed April 21, 2011.
81. Available at: http://sciencelinks.jp/j-east/article/200514/000020051405A0586947.php. Accessed April 21, 2011.
82. Available at: http://sciencelinks.jp/j-east/article/200512/000020051205A0483228.php. Accessed April 21, 2011.
83. Camera E, Mastrofrancesco A, Fabbri C, et al. Astaxanthin, canthaxanthin and beta-carotene differently affect UVA-induced oxidative damage and expression of oxidative stress-responsive enzymes. Exp Dermatol. 2009 Mar;18(3):222-31.
84. Lyons NM, O’Brien NM. Modulatory effects of an algal extract containing astaxanthin on UVA-irradiated cells in culture. J Dermatol Sci. 2002 Oct;30(1):73-84.
85. Andersen LP, Holck S, Kupcinskas L, et al. Gastric inflammatory markers and interleukins in patients with functional dyspepsia treated with astaxanthin. FEMS Immunol Med Microbiol. 2007 Jul;50(2):244-8.